<SEC-DOCUMENT>0001104659-24-095806.txt : 20240903
<SEC-HEADER>0001104659-24-095806.hdr.sgml : 20240903
<ACCEPTANCE-DATETIME>20240830181313
ACCESSION NUMBER:		0001104659-24-095806
CONFORMED SUBMISSION TYPE:	N-PX
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240903
DATE AS OF CHANGE:		20240830
EFFECTIVENESS DATE:		20240903

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			abrdn Life Sciences Investors
		CENTRAL INDEX KEY:			0000884121
		ORGANIZATION NAME:           	
		IRS NUMBER:				043147016
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		N-PX
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-06565
		FILM NUMBER:		241271407

	BUSINESS ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		6177728515

	MAIL ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKLA LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	20141015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	H&Q LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	19920929
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-PX
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?>
<edgarSubmission xmlns="http://www.sec.gov/edgar/npx" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>N-PX</submissionType>
    <filerInfo>
      <registrantType>RMIC</registrantType>
      <liveTestFlag>LIVE</liveTestFlag>
      <filer>
        <issuerCredentials>
          <cik>0000884121</cik>
          <ccc>XXXXXXXX</ccc>
          <!--Field: Pseudo-Tag; ID: Name; Data:-->
        </issuerCredentials>
      </filer>
      <flags>
        <overrideInternetFlag>false</overrideInternetFlag>
        <confirmingCopyFlag>false</confirmingCopyFlag>
      </flags>
      <investmentCompanyType>N-2</investmentCompanyType>
      <periodOfReport>06/30/2024</periodOfReport>
    </filerInfo>
  </headerData>
  <formData>
    <coverPage>
      <yearOrQuarter>YEAR</yearOrQuarter>
      <reportCalendarYear>2024</reportCalendarYear>
      <reportingPerson>
        <name>abrdn Life Sciences Investors</name>
        <phoneNumber>215-405-5700</phoneNumber>
        <address>
          <com:street1>1911 Market Street, Suite 200</com:street1>
          <com:city>Philadelphia</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>19103</com:zipCode>
        </address>
      </reportingPerson>
      <agentForService>
        <name>Lucia Sitar, Esq.</name>
        <address>
          <com:street1>1911 Market Street, Suite200</com:street1>
          <com:city>Philadelphia</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>19103</com:zipCode>
        </address>
      </agentForService>
      <reportInfo>
        <reportType>FUND VOTING REPORT</reportType>
      </reportInfo>
      <fileNumber>811-06565</fileNumber>
      <explanatoryInformation>
        <explanatoryChoice>N</explanatoryChoice>
      </explanatoryInformation>
    </coverPage>
    <summaryPage>
      <otherIncludedManagersCount>0</otherIncludedManagersCount>
    </summaryPage>
    <seriesPage>
      <seriesCount>0</seriesCount>
    </seriesPage>
    <signaturePage>
      <reportingPerson>abrdn Life Sciences Investors</reportingPerson>
      <txSignature>Alan Goodson</txSignature>
      <txPrintedSignature>Alan Goodson</txPrintedSignature>
      <txTitle>President (Principal Executive Officer)</txTitle>
      <txAsOfDate>08/30/2024</txAsOfDate>
    </signaturePage>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>PROXY VOTING RECORD
<SEQUENCE>2
<FILENAME>ProxyVotingTable.xml
<TEXT>
<XML>
<?xml version="1.0" ?>
<proxyVoteTable xmlns="http://www.sec.gov/edgar/document/npxproxy/informationtable">
  <proxyTable>
    <issuerName>NOVAVAX, INC.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>07/11/2023</meetingDate>
    <voteDescription>Election of Class I directors to serve on the Board of Directors, each for a three-year term expiring at the 2026 Annual Meeting of Stockholders: John C. Jacobs</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1412.000000</sharesVoted>
    <sharesOnLoan>25200.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1412.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NOVAVAX, INC.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>07/11/2023</meetingDate>
    <voteDescription>Election of Class I directors to serve on the Board of Directors, each for a three-year term expiring at the 2026 Annual Meeting of Stockholders: Gregg H. Alton. J.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1412.000000</sharesVoted>
    <sharesOnLoan>25200.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1412.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NOVAVAX, INC.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>07/11/2023</meetingDate>
    <voteDescription>Election of Class I directors to serve on the Board of Directors, each for a three-year term expiring at the 2026 Annual Meeting of Stockholders: Richard J. Rodgers</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1412.000000</sharesVoted>
    <sharesOnLoan>25200.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1412.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NOVAVAX, INC.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>07/11/2023</meetingDate>
    <voteDescription>The approval, on an advisory basis, of the compensation paid to our Named Executive Officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1412.000000</sharesVoted>
    <sharesOnLoan>25200.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1412.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NOVAVAX, INC.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>07/11/2023</meetingDate>
    <voteDescription>The approval, on an advisory basis, of holding future executive compensation advisory votes every three years, every two years, or every year.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1412.000000</sharesVoted>
    <sharesOnLoan>25200.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>1412.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NOVAVAX, INC.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>07/11/2023</meetingDate>
    <voteDescription>Amendment to the Second Amended and Restated Certificate of Incorporation of Novavax, Inc., as amended, to reflect Delaware law provisions allowing officer exculpation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1412.000000</sharesVoted>
    <sharesOnLoan>25200.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1412.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NOVAVAX, INC.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>07/11/2023</meetingDate>
    <voteDescription>Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentve Plan, as amended to increase the number of shares of common stock available for issuance thereunder by 6,170,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1412.000000</sharesVoted>
    <sharesOnLoan>25200.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1412.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>NOVAVAX, INC.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>07/11/2023</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1412.000000</sharesVoted>
    <sharesOnLoan>25200.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1412.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HORIZON THERAPEUTICS PLC</issuerName>
    <meetingDate>07/27/2023</meetingDate>
    <voteDescription>Election of Class III Director Nominees: Gino Santini</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>21912.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>21912.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HORIZON THERAPEUTICS PLC</issuerName>
    <meetingDate>07/27/2023</meetingDate>
    <voteDescription>Election of Class III Director Nominees: James Shannon, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>21912.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>21912.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HORIZON THERAPEUTICS PLC</issuerName>
    <meetingDate>07/27/2023</meetingDate>
    <voteDescription>Election of Class III Director Nominees: Timothy P. Walbert</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>21912.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>21912.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HORIZON THERAPEUTICS PLC</issuerName>
    <meetingDate>07/27/2023</meetingDate>
    <voteDescription>Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023, and authorization of the Audit Committee to determine the auditors' remuneration.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>21912.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>21912.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HORIZON THERAPEUTICS PLC</issuerName>
    <meetingDate>07/27/2023</meetingDate>
    <voteDescription>Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in this Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>21912.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>21912.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SPECTRUM PHARMACEUTICALS, INC.</issuerName>
    <cusip>84763A108</cusip>
    <isin>US84763A1088</isin>
    <meetingDate>07/27/2023</meetingDate>
    <voteDescription>ADOPTION OF THE MERGER AGREEMENT. i.e., to adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), a copy of which is attached as Annex A to the accompanying joint proxy statement/prospectus (the "Spectrum merger proposal").</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>34880.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>34880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SPECTRUM PHARMACEUTICALS, INC.</issuerName>
    <cusip>84763A108</cusip>
    <isin>US84763A1088</isin>
    <meetingDate>07/27/2023</meetingDate>
    <voteDescription>ADVISORY NON BINDING VOTE ON MERGER RELATED COMPENSATION FOR NAMED EXECUTIVE OFFICERS. i.e., a proposal to approve, on an advisory (non-binding) basis, the compensation that will or may be paid to Spectrum's named executive officers in connection with the merger.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>34880.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>34880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SPECTRUM PHARMACEUTICALS, INC.</issuerName>
    <cusip>84763A108</cusip>
    <isin>US84763A1088</isin>
    <meetingDate>07/27/2023</meetingDate>
    <voteDescription>ADJOURNMENT OF SPECTRUM SPECIAL MEETING. i.e., a proposal to approve the adjournment of the Spectrum special meeting to solicit additional proxies if there are not sufficient votes cast at the Spectrum special meeting to approve the Spectrum merger proposal or to ensure that any supplemental or amended disclosure, including any supplement or amendment to the enclosed joint proxy statement/prospectus, is timely provided to Spectrum stockholders.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>34880.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>34880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>CHINOOK THERAPEUTICS, INC.</issuerName>
    <cusip>16961L106</cusip>
    <meetingDate>08/02/2023</meetingDate>
    <voteDescription>To consider and vote upon the proposal to adopt the Agreement and Plan of Merger, dated as of June 11, 2023 (which, as it may be amended from time to time, we refer to as the "Merger Agreement"), by and among Chinook Therapeutics, Inc., a Delaware corporation (the "Company") Novartis AG, a company organized under the laws of Switzerland ("Novartis"), and Cherry Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Merger Sub"), pursuant to which Merger Sub will be merged with and into the Company (the "Merger"), with the Company to survive the Merger as an indirect wholly owned subsidiary of Novartis.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>59063.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>59063.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>CHINOOK THERAPEUTICS, INC.</issuerName>
    <cusip>16961L106</cusip>
    <meetingDate>08/02/2023</meetingDate>
    <voteDescription>To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation that may be paid or become payable to Chinook's named executive officers in connection with the Merger.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>59063.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>59063.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>CHINOOK THERAPEUTICS, INC.</issuerName>
    <cusip>16961L106</cusip>
    <meetingDate>08/02/2023</meetingDate>
    <voteDescription>To consider and vote upon the proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve the proposal to adopt the Merger Agreement at the time of the Special Meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>59063.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>59063.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>JAZZ PHARMACEUTICALS PLC</issuerName>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>08/03/2023</meetingDate>
    <voteDescription>To elect four nominees for director named below to hold office until the 2026 Annual General Meeting of Shareholders: Bruce C. Cozadd</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27751.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27751.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>JAZZ PHARMACEUTICALS PLC</issuerName>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>08/03/2023</meetingDate>
    <voteDescription>To elect four nominees for director named below to hold office until the 2026 Annual General Meeting of Shareholders: Heather Ann McSharry</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27751.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27751.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>JAZZ PHARMACEUTICALS PLC</issuerName>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>08/03/2023</meetingDate>
    <voteDescription>To elect four nominees for director named below to hold office until the 2026 Annual General Meeting of Shareholders: Anne O'Riordan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27751.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27751.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>JAZZ PHARMACEUTICALS PLC</issuerName>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>08/03/2023</meetingDate>
    <voteDescription>To elect four nominees for director named below to hold office until the 2026 Annual General Meeting of Shareholders: Rick E. Winningham</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27751.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27751.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>JAZZ PHARMACEUTICALS PLC</issuerName>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>08/03/2023</meetingDate>
    <voteDescription>To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2023 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27751.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27751.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>JAZZ PHARMACEUTICALS PLC</issuerName>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>08/03/2023</meetingDate>
    <voteDescription>To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27751.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27751.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>JAZZ PHARMACEUTICALS PLC</issuerName>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>08/03/2023</meetingDate>
    <voteDescription>To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27751.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27751.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>JAZZ PHARMACEUTICALS PLC</issuerName>
    <isin>IE00B4Q5ZN47</isin>
    <meetingDate>08/03/2023</meetingDate>
    <voteDescription>To approve any motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 4.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27751.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27751.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IMMUNOVANT INC</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/21/2023</meetingDate>
    <voteDescription>To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: Peter Salzmann, M.D., M.B.A.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>150400.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>150400.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IMMUNOVANT INC</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/21/2023</meetingDate>
    <voteDescription>To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: Douglas Hughes</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>150400.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>150400.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IMMUNOVANT INC</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/21/2023</meetingDate>
    <voteDescription>To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: George Migausky</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>150400.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>150400.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IMMUNOVANT INC</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/21/2023</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of our Board of Directors of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending March 31,2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>150400.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>150400.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IMMUNOVANT INC</issuerName>
    <cusip>45258J102</cusip>
    <isin>US45258J1025</isin>
    <meetingDate>08/21/2023</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>150400.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>150400.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ENDO INTERNATIONAL PLC</issuerName>
    <isin>IE00BJ3V9050</isin>
    <meetingDate>09/07/2023</meetingDate>
    <voteDescription>To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders: Mark G. Barberio</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>29100.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>29100.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ENDO INTERNATIONAL PLC</issuerName>
    <isin>IE00BJ3V9050</isin>
    <meetingDate>09/07/2023</meetingDate>
    <voteDescription>To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders: Jennifer M. Chao</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>29100.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>29100.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ENDO INTERNATIONAL PLC</issuerName>
    <isin>IE00BJ3V9050</isin>
    <meetingDate>09/07/2023</meetingDate>
    <voteDescription>To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders: Blaise Coleman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>29100.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>29100.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ENDO INTERNATIONAL PLC</issuerName>
    <isin>IE00BJ3V9050</isin>
    <meetingDate>09/07/2023</meetingDate>
    <voteDescription>To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders: Shane M. Cooke</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>29100.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>29100.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ENDO INTERNATIONAL PLC</issuerName>
    <isin>IE00BJ3V9050</isin>
    <meetingDate>09/07/2023</meetingDate>
    <voteDescription>To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders: Nancy J. Hutson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>29100.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>29100.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ENDO INTERNATIONAL PLC</issuerName>
    <isin>IE00BJ3V9050</isin>
    <meetingDate>09/07/2023</meetingDate>
    <voteDescription>To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders: Michael Hyatt</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>29100.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>29100.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ENDO INTERNATIONAL PLC</issuerName>
    <isin>IE00BJ3V9050</isin>
    <meetingDate>09/07/2023</meetingDate>
    <voteDescription>To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders: William P. Montague</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>29100.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>29100.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ENDO INTERNATIONAL PLC</issuerName>
    <isin>IE00BJ3V9050</isin>
    <meetingDate>09/07/2023</meetingDate>
    <voteDescription>To re-elect, by separate resolutions, the following eight members to our Board of Directors to serve until the next Annual Meeting of Shareholders: M. Christine Smith</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>29100.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>29100.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ENDO INTERNATIONAL PLC</issuerName>
    <isin>IE00BJ3V9050</isin>
    <meetingDate>09/07/2023</meetingDate>
    <voteDescription>To approve the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2023 and to authorize the Board of Directors, acting through the Audit &amp; Finance Committee, to determine the independent registered public accounting firm's remuneration.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>29100.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>29100.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ROIVANT SCIENCES LTD</issuerName>
    <isin>BMG762791017</isin>
    <meetingDate>09/12/2023</meetingDate>
    <voteDescription>To elect the Board's two nominees for Class II Director to serve for a three-year term: Daniel Gold</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>130291.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>130291.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ROIVANT SCIENCES LTD</issuerName>
    <isin>BMG762791017</isin>
    <meetingDate>09/12/2023</meetingDate>
    <voteDescription>To elect the Board's two nominees for Class II Director to serve for a three-year term: Meghan FitzGerald, DrPH</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>130291.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>130291.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ROIVANT SCIENCES LTD</issuerName>
    <isin>BMG762791017</isin>
    <meetingDate>09/12/2023</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Ernst &amp; Young LLP as Roivant's independent registered public accounting firm for Roivant's fiscal year ending March 31, 2024, to appoint Ernst &amp; Young LLP as auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for Roivant's fiscal year ending March 31, 2024, and to authorize the Board, through the Audit Committee, to set the remuneration for Ernst &amp; Young LLP as Roivant's auditor for Roivant's fiscal year ending March 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>130291.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>130291.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>REATA PHARMACEUTICALS, INC.</issuerName>
    <cusip>75615P103</cusip>
    <meetingDate>09/21/2023</meetingDate>
    <voteDescription>To approve and adopt the Agreement and Plan of Merger, dated as of July 28, 2023, as such agreement may be amended from time to time (the "Merger Agreement"), by and among Biogen Inc., a Delaware corporation ("Biogen"), River Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of Biogen ("Merger Sub"), and Reata Pharmaceuticals, Inc. ("Reata"), pursuant to which Merger Sub will be merged with and into Reata, with Reata surviving as a wholly-owned subsidiary of Biogen (the "Merger").</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>11300.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>11300.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>REATA PHARMACEUTICALS, INC.</issuerName>
    <cusip>75615P103</cusip>
    <meetingDate>09/21/2023</meetingDate>
    <voteDescription>To approve, on an advisory, non-binding basis, compensation that will or may be paid or become payable to Reata's named executive officers in connection with the Merger contemplated by the Merger Agreement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>11300.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>11300.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>REATA PHARMACEUTICALS, INC.</issuerName>
    <cusip>75615P103</cusip>
    <meetingDate>09/21/2023</meetingDate>
    <voteDescription>To approve to adjourn the Special Meeting to a later date if necessary and appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>11300.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>11300.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2024 Annual Meeting of Stockholders. Director of Nominees: Mitchel Sayare, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2024 Annual Meeting of Stockholders. Director of Nominees: Vipin K. Garg, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2024 Annual Meeting of Stockholders. Director of Nominees: David J. Drutz, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2024 Annual Meeting of Stockholders. Director of Nominees: John M. Gill</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2024 Annual Meeting of Stockholders. Director of Nominees: Philip L. Hodges</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2024 Annual Meeting of Stockholders. Director of Nominees: Diane Jorkasky, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2024 Annual Meeting of Stockholders. Director of Nominees: Wayne Pisano</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2024 Annual Meeting of Stockholders. Director of Nominees: Klaus O. Schafer, M.D., MPH</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2024 Annual Meeting of Stockholders. Director of Nominees: Catherine Sohn, Pharm D</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Vote to ratify the appointment of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Hold an advisory vote on the compensation of the Company's named executive officers as disclosed in the attached Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Hold an advisory vote on the frequency of the advisory vote on the compensation of the Company's named executive officers as disclosed in the attached Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Altimmune, Inc.</issuerName>
    <cusip>02155H200</cusip>
    <isin>US02155H2004</isin>
    <meetingDate>09/28/2023</meetingDate>
    <voteDescription>Approve the authorization to adjourn the Annual Meeting, if necessary or appropriate, to solicit additional proxies in favor of the foregoing proposals if there are not sufficient votes to approve the proposals.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>75000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>75000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>PRAXIS PRECISION MEDICINES, INC.</issuerName>
    <cusip>74006W108</cusip>
    <isin>US74006W1080</isin>
    <meetingDate>11/06/2023</meetingDate>
    <voteDescription>Approval of amendments to our Amended and Restated Certificate of Incorporation, to give our Board of Directors discretionary authority to effect a reverse stock split of all of the outstanding shares of our Common Stock, at a ratio ranging from any whole number between 1-for-5 and 1-for-25, as determined by our Board in its discretion (the "Reverse Stock Split Proposal").</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>23594.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>23594.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>PRAXIS PRECISION MEDICINES, INC.</issuerName>
    <cusip>74006W108</cusip>
    <isin>US74006W1080</isin>
    <meetingDate>11/06/2023</meetingDate>
    <voteDescription>Approval of a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>23594.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>23594.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>UNIQURE N.V.</issuerName>
    <isin>NL0010696654</isin>
    <meetingDate>11/15/2023</meetingDate>
    <voteDescription>Resolution to approve the amendment and restatement of the Company's 2014 Share Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>312788.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>UNIQURE N.V.</issuerName>
    <isin>NL0010696654</isin>
    <meetingDate>11/15/2023</meetingDate>
    <voteDescription>If Voting Proposal No. 1 is adopted, resolution to approve an increase in the number of authorized shares under the amendment and restatement of the Company's 2014 Share Incentive Plan and to authorize the Board as the competent body to issue ordinary shares and grant rights to subscribe for ordinary shares pursuant to such Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>312788.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mirati Therapeutics, Inc.</issuerName>
    <cusip>60468T105</cusip>
    <isin>US60468T1051</isin>
    <meetingDate>12/13/2023</meetingDate>
    <voteDescription>To adopt the Agreement and Plan of Merger (the "Merger Agreement"), dated October 8, 2023, by and among Mirati Therapeutics, Inc. ("Mirati"), Bristol-Myers Squibb Company ("Parent") and Vineyard Merger Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the form of contingent value rights agreement to be entered into at or immediately prior to the effective time of the Merger by Parent and a rights agent reasonably acceptable to Mirati, pursuant to which Merger Sub will merge with and into Mirati (the "Merger "), with Mirati surviving the Merger as a wholly owned subsidiary of Parent.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22852.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>22852.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mirati Therapeutics, Inc.</issuerName>
    <cusip>60468T105</cusip>
    <isin>US60468T1051</isin>
    <meetingDate>12/13/2023</meetingDate>
    <voteDescription>To approve, by non-binding, advisory vote, compensation that may be paid or become payable by Mirati to its named executive officers in connection with the Merger.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22852.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>22852.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mirati Therapeutics, Inc.</issuerName>
    <cusip>60468T105</cusip>
    <isin>US60468T1051</isin>
    <meetingDate>12/13/2023</meetingDate>
    <voteDescription>To approve the adjournment of the special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the special meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22852.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>22852.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>VYNE Therapeutics Inc.</issuerName>
    <cusip>92941V308</cusip>
    <isin>US92941V3087</isin>
    <meetingDate>12/13/2023</meetingDate>
    <voteDescription>To elect one Class II director to hold office until the 2026 Annual Meeting of Stockholders or until her successor is elected as a Class II director: Sharon Barbari</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2255.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>2255.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>VYNE Therapeutics Inc.</issuerName>
    <cusip>92941V308</cusip>
    <isin>US92941V3087</isin>
    <meetingDate>12/13/2023</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Company's Board of Directors of Baker Tilly US, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2255.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2255.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>VYNE Therapeutics Inc.</issuerName>
    <cusip>92941V308</cusip>
    <isin>US92941V3087</isin>
    <meetingDate>12/13/2023</meetingDate>
    <voteDescription>To approve the 2023 Equity Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2255.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2255.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>12/18/2023</meetingDate>
    <voteDescription>Amend Articles of Association</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>487283.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>487283.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Precision BioSciences, Inc.</issuerName>
    <cusip>74019P207</cusip>
    <isin>US74019P2074</isin>
    <meetingDate>01/18/2024</meetingDate>
    <voteDescription>Approval of amendments to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio ranging from any whole number between 1-for-10 and 1-for-30, as determined by the Board in its discretion, subject to the Board's authority to abandon such amendments.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>69727.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>69727.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Precision BioSciences, Inc.</issuerName>
    <cusip>74019P207</cusip>
    <isin>US74019P2074</isin>
    <meetingDate>01/18/2024</meetingDate>
    <voteDescription>Approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal 1.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>69727.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>69727.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>00211Y506</cusip>
    <isin>US00211Y5069</isin>
    <meetingDate>01/30/2024</meetingDate>
    <voteDescription>Election of Directors: Dr. Michael R. Bristow</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>00211Y506</cusip>
    <isin>US00211Y5069</isin>
    <meetingDate>01/30/2024</meetingDate>
    <voteDescription>Election of Directors: Mr. Robert E. Conway</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>00211Y506</cusip>
    <isin>US00211Y5069</isin>
    <meetingDate>01/30/2024</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ARCA biopharma, Inc.</issuerName>
    <cusip>00211Y506</cusip>
    <isin>US00211Y5069</isin>
    <meetingDate>01/30/2024</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32461.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>32461.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SAGE Therapeutics, Inc.</issuerName>
    <cusip>78667J108</cusip>
    <isin>US78667J1088</isin>
    <meetingDate>01/31/2024</meetingDate>
    <voteDescription>To approve a one-time stock option exchange program for non-executive officer employees of Sage (the ''Option Exchange Proposal'').</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>22773.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SAGE Therapeutics, Inc.</issuerName>
    <cusip>78667J108</cusip>
    <isin>US78667J1088</isin>
    <meetingDate>01/31/2024</meetingDate>
    <voteDescription>To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Option Exchange Proposal.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>22773.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Harpoon Therapeutics, Inc.</issuerName>
    <cusip>41358P205</cusip>
    <isin>US41358P2056</isin>
    <meetingDate>03/08/2024</meetingDate>
    <voteDescription>Adoption of the Agreement and Plan of Merger, dated as of January 7, 2024 (as it may be amended from time to time, the "Merger Agreement"), by and among Merck Sharp &amp; Dohme LLC, a New Jersey limited liability company ("Merck"), Hawaii Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Merck ("Merger Sub"), and Harpoon Therapeutics, Inc. ("Harpoon"). Pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into Harpoon, with Harpoon continuing as the surviving corporation and a wholly owned subsidiary of Merck.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>25991.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>25991.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Harpoon Therapeutics, Inc.</issuerName>
    <cusip>41358P205</cusip>
    <isin>US41358P2056</isin>
    <meetingDate>03/08/2024</meetingDate>
    <voteDescription>Approval of a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>25991.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>25991.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Karuna Therapeutics, Inc.</issuerName>
    <cusip>48576A100</cusip>
    <isin>US48576A1007</isin>
    <meetingDate>03/12/2024</meetingDate>
    <voteDescription>To adopt the Agreement and Plan of Merger, dated as of December 22, 2023 (the "merger agreement"), among Karuna Therapeutics, Inc. ("Karuna"), Bristol-Myers Squibb Company ("Bristol-Myers Squibb"), and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers Squibb Company ("Merger Sub"), pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will be merged with and into Karuna, and Karuna will survive the merger as a wholly owned subsidiary of Bristol-Myers Squibb.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>12032.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>12032.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Karuna Therapeutics, Inc.</issuerName>
    <cusip>48576A100</cusip>
    <isin>US48576A1007</isin>
    <meetingDate>03/12/2024</meetingDate>
    <voteDescription>To approve, on an advisory, non-binding basis, certain compensation that will or may be paid by Karuna to its named executive officers that is based on or otherwise relates to the merger of Merger Sub with and into Karuna pursuant to the merger agreement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>12032.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>12032.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Karuna Therapeutics, Inc.</issuerName>
    <cusip>48576A100</cusip>
    <isin>US48576A1007</isin>
    <meetingDate>03/12/2024</meetingDate>
    <voteDescription>To adjourn the special meeting from time to time, if necessary or appropriate, as determined in good faith by the board of directors of Karuna including for the purpose of soliciting additional votes for the approval of the proposal to adopt the merger agreement if there are insufficient votes at the time of the special meeting to approve the proposal to adopt the merger agreement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>12032.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>12032.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Approval of the annual financial statements for the fiscal year ended December 31, 2023 - Discharge of the President for the performance of his duties during the past fiscal year</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Approval of the results of the fiscal year ended December 31, 2023</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Agreed that the Company's AGM meeting organized per Article L. 227-10 of the French Commercial Code</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Approval of the amendment No.4 dated January 8, 2024 to the consulting agreement entered into on May 6, 2020 between the Company and Stone Atlanta Estates LLC (formerly Stone Sunny Isles, Inc.), of which Mr. Pierre Legault is president, the terms of which are described in the special report of the Statutory Auditor</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Approval of a payment to Stone Atlanta Estates LLC of an additional fee of EUR 75,000 (excl. VAT) in the scope of the consulting agreement entered into on May 6, 2020, as amended, subject to the completion of the acquisition of the Company by AstraZeneca.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Renewal of James Hindman as Board member</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Renewal of Elisabeth Svanberg as Board member</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Renewal of Stefan Larson as Board member</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Renewal of Raphael Wisniewski as Board member</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amolyt Pharma</issuerName>
    <meetingDate>04/09/2024</meetingDate>
    <voteDescription>Resolution to amend article 26 of the bylaws "Loss of half the share capital" as follows, in order to update it with the new provisions of article L. 225-248 of the French Commercial Code concerning the procedures for restoring the shareholders' equity in the event of a loss of half the share capital</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SHAREHOLDER RIGHTS AND DEFENSES</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>686930.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>686930.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Accept Financial Statements and Statutory Reports</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Approve Dividends</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Reappoint PricewaterhouseCoopers LLP as Auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Authorise Board to Fix Remuneration of Auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Michel Demare as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Pascal Soriot as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Aradhana Sarin as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Philip Broadley as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Euan Ashley as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Deborah DiSanzo as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Diana Layfield as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Elect Anna Manz as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Sheri McCoy as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Tony Mok as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Nazneen Rahman as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Andreas Rummelt as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Re-elect Marcus Wallenberg as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Approve Remuneration Report</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Approve Remuneration Policy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Amend Performance Share Plan 2020</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Authorise UK Political Donations and Expenditure</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>OTHER SOCIAL ISSUES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Authorise Issue of Equity</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Authorise Issue of Equity without Pre-emptive Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital Investment</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Authorise Market Purchase of Ordinary Shares</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>AstraZeneca PLC</issuerName>
    <cusip>046353108</cusip>
    <isin>US0463531089</isin>
    <meetingDate>04/11/2024</meetingDate>
    <voteDescription>Authorise the Company to Call General Meeting with Two Weeks' Notice</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>270376.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>270376.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IQVIA Holdings Inc.</issuerName>
    <cusip>46266C105</cusip>
    <isin>US46266C1053</isin>
    <meetingDate>04/16/2024</meetingDate>
    <voteDescription>The election of six directors: Ari Bousbib</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1647.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1647.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IQVIA Holdings Inc.</issuerName>
    <cusip>46266C105</cusip>
    <isin>US46266C1053</isin>
    <meetingDate>04/16/2024</meetingDate>
    <voteDescription>The election of six directors: Carol J. Burt</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1647.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1647.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IQVIA Holdings Inc.</issuerName>
    <cusip>46266C105</cusip>
    <isin>US46266C1053</isin>
    <meetingDate>04/16/2024</meetingDate>
    <voteDescription>The election of six directors: Colleen A. Goggins</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1647.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1647.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IQVIA Holdings Inc.</issuerName>
    <cusip>46266C105</cusip>
    <isin>US46266C1053</isin>
    <meetingDate>04/16/2024</meetingDate>
    <voteDescription>The election of six directors: John M. Leonard, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1647.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1647.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IQVIA Holdings Inc.</issuerName>
    <cusip>46266C105</cusip>
    <isin>US46266C1053</isin>
    <meetingDate>04/16/2024</meetingDate>
    <voteDescription>The election of six directors: Todd B. Sisitsky</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1647.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1647.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IQVIA Holdings Inc.</issuerName>
    <cusip>46266C105</cusip>
    <isin>US46266C1053</isin>
    <meetingDate>04/16/2024</meetingDate>
    <voteDescription>The election of six directors: Sheila A. Stamps</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1647.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1647.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IQVIA Holdings Inc.</issuerName>
    <cusip>46266C105</cusip>
    <isin>US46266C1053</isin>
    <meetingDate>04/16/2024</meetingDate>
    <voteDescription>Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay).</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1647.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1647.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IQVIA Holdings Inc.</issuerName>
    <cusip>46266C105</cusip>
    <isin>US46266C1053</isin>
    <meetingDate>04/16/2024</meetingDate>
    <voteDescription>If properly presented, a stockholder proposal concerning political spending.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>OTHER SOCIAL ISSUES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>1647.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1647.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>IQVIA Holdings Inc.</issuerName>
    <cusip>46266C105</cusip>
    <isin>US46266C1053</isin>
    <meetingDate>04/16/2024</meetingDate>
    <voteDescription>Ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA's independent registered public accounting firm for 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1647.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1647.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To re-elect Lisa Deschamps as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To re-elect Martin Edwards as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To re-elect Sven Anders Ullman as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To re-elect Christina Ackermann as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To re-elect Michael Austwick as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended 31 December 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended 31 December 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To receive and approve the U.K. Directors' Remuneration Policy.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To approve an increase in the maximum aggregate level of Non-Executive Director annual remuneration (by way of fee) in accordance with Article 21.4 of the Company's Articles of Association to pounds750,000 per annum on an ongoing basis.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To appoint Ernst &amp; Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds8,345,745 (being up to a maximum of 166,914,908 shares representing 25% of the Company's existing ordinary share capital as at the close of business on March 13, 2024 (being the latest practicable date prior to publication of this document)).</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Verona Pharma Plc</issuerName>
    <cusip>G9337X139</cusip>
    <isin>GB00BYW2KH80</isin>
    <meetingDate>04/26/2024</meetingDate>
    <voteDescription>To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if Section 561(1) of the Companies Act does not apply to any such allotment.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>5.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Election of the following directors, each to serve a three-year term: Katherine Baicker, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Election of the following directors, each to serve a three-year term: J. Erik Fyrwald</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Election of the following directors, each to serve a three-year term: Jamere Jackson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Election of the following directors, each to serve a three-year term: Gabrielle Sulzberger</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Approval, on an advisory basis, of the compensation paid to the company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as the independent auditor for 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Approval of amendments to the company's Articles of Incorporation to eliminate the classified board structure.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SHAREHOLDER RIGHTS AND DEFENSES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Approval of amendments to the company's Articles of Incorporation to eliminate supermajority voting provisions.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Shareholder proposal to publish an annual report disclosing lobbying activities.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>OTHER SOCIAL ISSUES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Shareholder proposal to report on effectiveness of the company's diversity, equity, and inclusion efforts.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIVERSITY, EQUITY, AND INCLUSION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Shareholder proposal to establish and report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>OTHER SOCIAL ISSUES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Eli Lilly and Company</issuerName>
    <cusip>532457108</cusip>
    <isin>US5324571083</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>Shareholder proposal to adopt a comprehensive human rights policy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>7661.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>7661.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Moderna, Inc.</issuerName>
    <cusip>60770K107</cusip>
    <isin>US60770K1079</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>To elect three Class III director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2027 annual meeting of shareholders and until his or her other respective successor is duly elected and qualified or such director's earlier death, resignation or removal: Robert Langer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107787.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>107787.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Moderna, Inc.</issuerName>
    <cusip>60770K107</cusip>
    <isin>US60770K1079</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>To elect three Class III director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2027 annual meeting of shareholders and until his or her other respective successor is duly elected and qualified or such director's earlier death, resignation or removal: Elizabeth Nabel, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107787.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107787.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Moderna, Inc.</issuerName>
    <cusip>60770K107</cusip>
    <isin>US60770K1079</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>To elect three Class III director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2027 annual meeting of shareholders and until his or her other respective successor is duly elected and qualified or such director's earlier death, resignation or removal: Elizabeth Tallett</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107787.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107787.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Moderna, Inc.</issuerName>
    <cusip>60770K107</cusip>
    <isin>US60770K1079</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107787.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>107787.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Moderna, Inc.</issuerName>
    <cusip>60770K107</cusip>
    <isin>US60770K1079</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107787.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107787.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Moderna, Inc.</issuerName>
    <cusip>60770K107</cusip>
    <isin>US60770K1079</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>To approve an amendment to the Amended and Restated Certificate of Incorporation to provide shareholders the right to call a special meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107787.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107787.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Moderna, Inc.</issuerName>
    <cusip>60770K107</cusip>
    <isin>US60770K1079</isin>
    <meetingDate>05/06/2024</meetingDate>
    <voteDescription>To approve an amendment to the Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107787.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107787.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Approve Remuneration Report</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Adopt Financial Statements and Statutory Reports</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Approve Allocation of Losses to the Retained Earnings of the Company</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Approve Discharge of Directors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Approve Remuneration Policy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Elect Brian L. Kotzin as Non-Executive Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Reelect Peter Verhaeghe as Non-Executive Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Reelect Pamela Klein as Non-Executive Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Grant Board Authority to Issue Shares Up To 10 Percent of Issued Capital and Exclude Pre-emptive Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Amend Articles of Association and Authorization to Execute the Deed of Amendment</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Ratify Deloitte Accountants B.V. as Auditors for the 2024 Financial Year</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>argenx SE</issuerName>
    <cusip>04016X101</cusip>
    <isin>US04016X1019</isin>
    <meetingDate>05/07/2024</meetingDate>
    <voteDescription>Ratify Ernst &amp; Young Accountants LLP as Auditors for the 2025 Financial Year</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>19873.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>19873.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: James C. Foster</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: Nancy C. Andrews</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: Robert Bertolini</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: Reshema Kemps-Polanco</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: Deborah T. Kochevar</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: George Llado, Sr.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: Martin W. Mackay</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: George E. Massaro</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: Craig B. Thompson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: Richard F. Wallman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Election of Directors: Virginia M. Wilson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Advisory Approval of 2023 Executive Officer Compensation</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Ratification of PricewaterhouseCoopers LLC as independent registered public accounting firm for 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Charles River Laboratories International, Inc.</issuerName>
    <cusip>159864107</cusip>
    <isin>US1598641074</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>Proposal to publish a report on non-human primates imported by Charles River Laboratories International, Inc.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>OTHER SOCIAL ISSUES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>14134.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14134.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. Kramer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish Manwani</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'Day</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. Rodriguez</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony Welters</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To ratify the selection of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To approve an amendment to our Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To vote on a stockholder proposal requesting that the Board include one member from the Company's non-management employees.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To vote on a stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company may deploy to minimize or mitigate these risks.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>OTHER SOCIAL ISSUES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Gilead Sciences, Inc.</issuerName>
    <cusip>375558103</cusip>
    <isin>US3755581036</isin>
    <meetingDate>05/08/2024</meetingDate>
    <voteDescription>To vote on a stockholder proposal requesting that the Board adopt a policy requiring the Company's named executive officers to retain at least 25% of net-after tax shares of stock acquired through equity pay programs until reaching normal retirement age (at least age 60).</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>412398.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>412398.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Election of Directors: Juan Andres</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Election of Directors: John Carethers</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Election of Directors: Lan Kang</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Election of Directors: Joseph Massaro</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Election of Directors: Mala Murthy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Election of Directors: Jonathan Peacock</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Election of Directors: Michael Severino</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Election of Directors: Michael Stubblefield</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Election of Directors: Gregory Summe</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Approve the Officer Exculpation Amendment and Other Immaterial Amendments to our Certificate of Incorporation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Ratification of the Appointment of Deloitte &amp; Touche LLP as the Company's independent registered accounting firm for 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avantor, Inc.</issuerName>
    <cusip>05352A100</cusip>
    <isin>US05352A1007</isin>
    <meetingDate>05/09/2024</meetingDate>
    <voteDescription>Approve, on an Advisory Basis, Named Executive Officer Compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37094.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>37094.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/13/2024</meetingDate>
    <voteDescription>Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: David R. Brennan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>63678.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>63678.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/13/2024</meetingDate>
    <voteDescription>Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Leo Lee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>63678.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>63678.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/13/2024</meetingDate>
    <voteDescription>Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Carol A. Schafer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>63678.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>63678.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/13/2024</meetingDate>
    <voteDescription>Election of four Class III directors, David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D., to serve until the 2027 Annual Meeting of Shareholders: Melvin Sharoky, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>63678.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>63678.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/13/2024</meetingDate>
    <voteDescription>An advisory vote on the 2023 compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>63678.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>63678.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/13/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>63678.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>63678.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Insmed Incorporated</issuerName>
    <cusip>457669307</cusip>
    <isin>US4576693075</isin>
    <meetingDate>05/13/2024</meetingDate>
    <voteDescription>Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>63678.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>63678.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>To elect two Class II Directors: Robert I. Blum</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>58348.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>58348.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>To elect two Class II Directors: Robert A. Hammington, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>58348.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>58348.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under such plan by 300,000 shares of common stock.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>58348.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>58348.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>To ratify the appointment by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>58348.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>58348.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Cytokinetics, Incorporated</issuerName>
    <cusip>23282W605</cusip>
    <isin>US23282W6057</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>58348.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>58348.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rallybio Corporation</issuerName>
    <cusip>75120L100</cusip>
    <isin>US75120L1008</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Class III Directors: Wendy K. Chung</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>377375.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>377375.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rallybio Corporation</issuerName>
    <cusip>75120L100</cusip>
    <isin>US75120L1008</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Class III Directors: Robert Hopfner</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>377375.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>377375.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rallybio Corporation</issuerName>
    <cusip>75120L100</cusip>
    <isin>US75120L1008</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Class III Directors: Ronald Hunt</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>377375.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>377375.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rallybio Corporation</issuerName>
    <cusip>75120L100</cusip>
    <isin>US75120L1008</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Class III Directors: Hui Liu</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>377375.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>377375.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Rallybio Corporation</issuerName>
    <cusip>75120L100</cusip>
    <isin>US75120L1008</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Deloitte &amp; Touche LLP as the independent registered public accounting firm.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>377375.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>377375.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Sangeeta Bhatia</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Lloyd Carney</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Alan Garber</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Reshma Kewalramani</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Michel Lagarde</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Jeffrey Leiden</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Diana McKenzie</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Bruce Sachs</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Jennifer Schneider</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Nancy Thornberry</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Election of Directors: Suketu Upadhyay</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Ratification of Ernst &amp; Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Advisory vote to approve named executive office compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Shareholder proposal, if properly presented at the meeting, regarding special shareholder meeting improvement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vertex Pharmaceuticals Incorporated</issuerName>
    <cusip>92532F100</cusip>
    <isin>US92532F1003</isin>
    <meetingDate>05/15/2024</meetingDate>
    <voteDescription>Shareholder proposal, if properly presented at the meeting, regarding a report on racial and gender pay gaps.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIVERSITY, EQUITY, AND INCLUSION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>100095.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>100095.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>To elect the following nominees as Class II directors of Alnylam: Dennis A. Ausiello, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60121.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60121.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>To elect the following nominees as Class II directors of Alnylam: Olivier Brandicourt, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60121.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60121.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>To elect the following nominees as Class II directors of Alnylam: Peter N. Kellogg</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60121.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60121.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>To elect the following nominees as Class II directors of Alnylam: David E.I. Pyott</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60121.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60121.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60121.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>60121.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alnylam Pharmaceuticals, Inc.</issuerName>
    <cusip>02043Q107</cusip>
    <isin>US02043Q1076</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60121.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>60121.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Yuval Cohen</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Alan Holmer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Avery W. Catlin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Rachelle Jacques</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: John Jenkins</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Peter Salzmann</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Anne Altmeyer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Yong Ben</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Approval of the Company's 2024 Equity Compensation Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Ratification of EisnerAmper LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Corbus Pharmaceuticals Holdings, Inc.</issuerName>
    <cusip>21833P301</cusip>
    <isin>US21833P3010</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5143.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>5143.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Frances Arnold, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Caroline D. Dorsa</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Robert S. Epstein, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Scott Gottlieb, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Gary S. Guthart, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Stephen P. MacMillan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Anna Richo</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Philip W. Schiller</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Susan E. Siegel</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Jacob Thaysen, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>Election of Directors: Scott B. Ullem</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 29, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Illumina, Inc.</issuerName>
    <cusip>452327109</cusip>
    <isin>US4523271090</isin>
    <meetingDate>05/16/2024</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>60493.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>60493.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approve Allocation of Income and Omission of Dividends</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approve Discharge of Management Board for Fiscal Year 2023</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approve Discharge of Supervisory Board for Fiscal Year 2023</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Ratify EY GmbH &amp; Co. KG as Auditors for Fiscal Year 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approve Remuneration Report</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approve Remuneration Policy for the Management Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approve Remuneration Policy for the Supervisory Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approve Issuance of Warrants/Bonds with Warrants Attached/Convertible Bonds without Preemptive Rights up to Aggregate Nominal Amount of EUR 3 Billion; Approve Creation of EUR 24.9 Million Pool of Capital to Guarantee Conversion Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Authorize Share Repurchase Program and Reissuance or Cancellation of Repurchased Shares</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Authorize Use of Financial Derivatives when Repurchasing Shares</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Amend Stock Option Plans 2017/19 and 2021</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approve Stock Option Plan for Key Employees; Approve Creation of EUR 6.2 Million Pool of Conditional Capital to Guarantee Conversion Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioNTech SE</issuerName>
    <cusip>09075V102</cusip>
    <isin>US09075V1026</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approve Affiliation Agreement with BioNTech Collaborations GmbH</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>EXTRAORDINARY TRANSACTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>37462.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>37462.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Election of Class I Directors: Suma M. Krishnan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>11887.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>11887.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Election of Class I Directors: Julian S. Gangolli</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>11887.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>11887.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Election of Class I Directors: Catherine Mazzacco</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>11887.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>11887.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>11887.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>11887.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Krystal Biotech, Inc.</issuerName>
    <cusip>501147102</cusip>
    <isin>US5011471027</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>11887.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>11887.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Election of Directors: Fred B. Davenport, Jr.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5284.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5284.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>Election of Directors: Cornelius P. McCarthy III</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5284.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5284.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5284.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>5284.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2024 Annual Meeting.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5284.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5284.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Medpace Holdings, Inc.</issuerName>
    <cusip>58506Q109</cusip>
    <isin>US58506Q1094</isin>
    <meetingDate>05/17/2024</meetingDate>
    <voteDescription>To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to begin phasing out the Company's classified Board of Directors so that directors up for election at and after the 2025 Annual Meeting of Stockholders will be elected annually.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SHAREHOLDER RIGHTS AND DEFENSES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>5284.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>5284.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Elizabeth M. Anderson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Barbara W. Bodem</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Athena Countouriotis</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Willard Dere</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Mark J. Enyedy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Alexander Hardy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Elaine J. Heron</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Maykin Ho</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Robert J. Hombach</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: Richard A. Meier</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>Election of Directors: David E.I. Pyott</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BioMarin Pharmaceutical Inc.</issuerName>
    <cusip>09061G101</cusip>
    <isin>US09061G1013</isin>
    <meetingDate>05/21/2024</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>122012.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>122012.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Marinus Pharmaceuticals, Inc.</issuerName>
    <cusip>56854Q200</cusip>
    <isin>US56854Q2003</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of three Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified: Elan Ezickson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>167418.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>167418.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Marinus Pharmaceuticals, Inc.</issuerName>
    <cusip>56854Q200</cusip>
    <isin>US56854Q2003</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of three Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified: Charles Austin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>167418.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>167418.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Marinus Pharmaceuticals, Inc.</issuerName>
    <cusip>56854Q200</cusip>
    <isin>US56854Q2003</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of three Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified: Marvin H. Johnson, Jr.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>167418.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>167418.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Marinus Pharmaceuticals, Inc.</issuerName>
    <cusip>56854Q200</cusip>
    <isin>US56854Q2003</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>167418.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>167418.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Marinus Pharmaceuticals, Inc.</issuerName>
    <cusip>56854Q200</cusip>
    <isin>US56854Q2003</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>167418.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>167418.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Marinus Pharmaceuticals, Inc.</issuerName>
    <cusip>56854Q200</cusip>
    <isin>US56854Q2003</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Approval of the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>167418.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>167418.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: William H. Rastetter, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38692.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38692.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: George J. Morrow</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38692.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38692.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Leslie V. Norwalk</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38692.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38692.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Christine A. Poon</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38692.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38692.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Advisory vote on the compensation paid to the Company's named executive officers;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38692.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>38692.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>To approve an amendment of the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 3,635,000 shares; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38692.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38692.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Neurocrine Biosciences, Inc.</issuerName>
    <cusip>64125C109</cusip>
    <isin>US64125C1099</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38692.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>38692.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Marc N. Casper</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Nelson J. Chai</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Ruby R. Chandy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: C. Martin Harris</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Tyler Jacks</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Jennifer M. Johnson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: R. Alexandra Keith</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: James C. Mullen</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Debora L. Spar</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Scott M. Sperling</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Election of Directors: Dion J. Weisler</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>An advisory vote to approve named executive officer compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Thermo Fisher Scientific Inc.</issuerName>
    <cusip>883556102</cusip>
    <isin>US8835561023</isin>
    <meetingDate>05/22/2024</meetingDate>
    <voteDescription>Shareholder Proposal: Simple Majority Vote.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>984.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>984.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/23/2024</meetingDate>
    <voteDescription>That the annual report and accounts for the year ended December 31, 2023, together with the directors' report and independent auditor's report thereon, be received and adopted.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256841.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>256841.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/23/2024</meetingDate>
    <voteDescription>That PricewaterhouseCoopers LLP ("PwC") be re-appointed as auditors to hold office from the conclusion of the annual general meeting until the conclusion of the next annual general meeting at which the Company's annual report and accounts are presented.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256841.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>256841.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/23/2024</meetingDate>
    <voteDescription>That the Audit and Risk Committee be authorized to determine PwC's remuneration.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256841.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>256841.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/23/2024</meetingDate>
    <voteDescription>That the directors' remuneration report (excluding the directors' remuneration policy), as set out in the Company's annual report and accounts for the year ended December 31, 2023, be approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256841.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>256841.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/23/2024</meetingDate>
    <voteDescription>That Dr. Denise Scots-Knight be re-appointed as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256841.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>256841.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/23/2024</meetingDate>
    <voteDescription>That Dr. Jeremy Bender be re-appointed as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256841.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ABSTAIN</howVoted>
        <sharesVoted>256841.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mereo BioPharma Group Plc</issuerName>
    <cusip>589492107</cusip>
    <isin>US5894921072</isin>
    <meetingDate>05/23/2024</meetingDate>
    <voteDescription>That Dr. Anders Ekblom be re-appointed as a director of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256841.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>256841.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>89bio, Inc.</issuerName>
    <cusip>282559103</cusip>
    <isin>US2825591033</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Election of Directors: To be elected for terms expiring in 2027: Steven Altschuler, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>206494.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>206494.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>89bio, Inc.</issuerName>
    <cusip>282559103</cusip>
    <isin>US2825591033</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Election of Directors: To be elected for terms expiring in 2027: Michael Hayden, M.B. Ch.B., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>206494.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>206494.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>89bio, Inc.</issuerName>
    <cusip>282559103</cusip>
    <isin>US2825591033</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Election of Directors: To be elected for terms expiring in 2027: Kathleen LaPorte</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>206494.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>206494.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>89bio, Inc.</issuerName>
    <cusip>282559103</cusip>
    <isin>US2825591033</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>206494.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>206494.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>89bio, Inc.</issuerName>
    <cusip>282559103</cusip>
    <isin>US2825591033</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approval of, on an advisory basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>206494.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>206494.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>89bio, Inc.</issuerName>
    <cusip>282559103</cusip>
    <isin>US2825591033</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Advisory vote on the frequency of future advisory votes on executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>206494.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>206494.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Accept Financial Statements and Statutory Reports</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Treatment of Net Loss</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Discharge of Board and Senior Management</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Reelect Anthony Rosenberg as Director and Board Chair</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Reelect Christina Ackermann as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Reelect Lionel Carnot as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Reelect Martijn Kleijwegt as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Reelect Geraldine O'Keeffe as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Reelect Riad Sherif as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Elect Robert Warner as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Elect Arshad Khanani as Director</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Reappoint Christina Ackermann as Member of the Compensation Committee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Reappoint Lionel Carnot as Member of the Compensation Committee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Appoint Robert Warner as Member of the Compensation Committee</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Ratify PricewaterhouseCoopers SA as Statutory Auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Designate PST Legal AG as Independent Proxy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Fixed Remuneration of Directors in the Amount of USD 522,855</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Equity-Based Remuneration of Directors in the Amount of USD 1.2 Million</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Fixed Remuneration of Executive Committee in the Amount of USD 2.5 Million</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Variable Remuneration of Executive Committee in the Amount of USD 1.8 Million</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Equity-Based Remuneration of Executive Committee in the Amount of USD 12.8 Million</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Remuneration Report (Non-Binding)</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Creation of Capital Band within the Upper Limit of CHF 681,655.50 and the Lower Limit of CHF 454,437.00 with or without Exclusion of Preemptive Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Creation of CHF 67,500 Pool of Conditional Capital for Bonds or Similar Debt Instruments</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Approve Creation of CHF 95,663.02 Pool of Conditional Capital for Employee Equity Plans</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Oculis Holding AG</issuerName>
    <cusip>H5870P102</cusip>
    <isin>CH1242303498</isin>
    <meetingDate>05/29/2024</meetingDate>
    <voteDescription>Transact Other Business (Voting)</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>0.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Elect Chairman of Meeting</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Approve Company Activity Report</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Accept Financial Statements and Statutory Reports; Approve Discharge of Management and Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Approve Treatment of Net Loss</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Reelect Albert Cha as Director For Two Years Term</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Reelect Lars Holtug as Director For Two Years Term</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Ratify Deloitte as Auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Amend Articles Re: Board-Related</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Approve Creation of DKK 9 Million Pool of Capital with Preemptive Rights</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ascendis Pharma A/S</issuerName>
    <cusip>04351P101</cusip>
    <isin>US04351P1012</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Approve Warrant Plan for Key Employees</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>45830.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>45830.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Mary C. Beckerle, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: S. Gail Eckhardt, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Maria C. Freire, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Tomas J. Heyman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: David E. Johnson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Michael M. Morrissey, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Robert L. Oliver, Jr.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Stelios Papadopoulos, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: George Poste, DVM, Ph.D., FRS</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Julie Anne Smith</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To elect the eleven nominees for director named in the accompanying Proxy Statement to hold office until the next Annual Meeting of Stockholders: Jack L. Wyszomierski</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as Exelixis' independent registered public accounting firm for the focal year ending January 3, 2025.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To amend and restate the Exelixis 2000 Employee Stock Purchase Plan to, among other things, increase the number of shares authorized for issuance by 6,000,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Exelixis, Inc.</issuerName>
    <cusip>30161Q104</cusip>
    <isin>US30161Q1040</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>186118.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>186118.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology Plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Election of directors to serve until the Company's 2025 Annual General Meeting: Scott Jackson, MBA</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology Plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Election of directors to serve until the Company's 2025 Annual General Meeting: Francis Cuss, M.B., B.Chir., FRCP</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology Plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Election of directors to serve until the Company's 2025 Annual General Meeting: Susan Altschuller, Ph.D., MBA</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology Plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Election of directors to serve until the Company's 2025 Annual General Meeting: Benjamin Hickey, MBA</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology Plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Election of directors to serve until the Company's 2025 Annual General Meeting: Caroline Loew, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mural Oncology Plc</issuerName>
    <cusip>G63365103</cusip>
    <isin>IE000LK2BOB4</isin>
    <meetingDate>05/30/2024</meetingDate>
    <voteDescription>Ratification, in a non-binding advisory vote, of the selection of PricewaterhouseCoopers LLP as the Company's independent auditor for the fiscal year ending December 31, 2024 and authorization, in a binding vote, of the board of directors, acting through the audit committee, to set the independent auditor's remuneration</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>14952.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>14952.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Emily Peterson Alva</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Shane M. Cooke</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: David A. Daglio, Jr.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Richard B. Gaynor, M.D</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Cato T. Laurencin, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Nancy S. Lurker</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Brian P. McKeon</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Richard F. Pops</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Nancy L. Snyderman, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Frank Anders Wilson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect as directors to serve a one-year term until the Company's 2025 annual general meeting of shareholders: Christopher I. Wright, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To approve, in a non-binding, advisory vote, the frequency of future advisory votes on the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To renew Board authority to allot and issue shares under Irish law.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Alkermes plc</issuerName>
    <cusip>G01767105</cusip>
    <isin>IE00B56GVS15</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>134657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>134657.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. Austin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Bradway</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. Drake</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. Druker</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Eckert</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. Garland</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar Ishrak</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler Jacks</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. Klotman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. Kullman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2025 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. Miles</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>Advisory vote to approve our executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To approve our Amgen Inc. Second Amended and Restated 2009 Equity incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amgen Inc.</issuerName>
    <cusip>031162100</cusip>
    <isin>US0311621009</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>To ratify the selection of Ernst &amp; Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>142104.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>142104.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Jay Flatley</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185311.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185311.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Marc Tessier-Lavigne, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185311.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185311.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>ELECTION OF DIRECTORS: Nancy Thornberry</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185311.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185311.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185311.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185311.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Denali Therapeutics Inc.</issuerName>
    <cusip>24823R105</cusip>
    <isin>US24823R1059</isin>
    <meetingDate>05/31/2024</meetingDate>
    <voteDescription>Advisory vote on executive compensation</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>185311.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>185311.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Quanterix Corporation</issuerName>
    <cusip>74766Q101</cusip>
    <isin>US74766Q1013</isin>
    <meetingDate>06/03/2024</meetingDate>
    <voteDescription>Election of Directors: Karen A. Flynn</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>18837.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>18837.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Quanterix Corporation</issuerName>
    <cusip>74766Q101</cusip>
    <isin>US74766Q1013</isin>
    <meetingDate>06/03/2024</meetingDate>
    <voteDescription>Election of Directors: Martin D. Madaus, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>18837.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>18837.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Quanterix Corporation</issuerName>
    <cusip>74766Q101</cusip>
    <isin>US74766Q1013</isin>
    <meetingDate>06/03/2024</meetingDate>
    <voteDescription>To approve, by a non-binding advisory vote, the compensation of our named executive officers, as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>18837.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>18837.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Quanterix Corporation</issuerName>
    <cusip>74766Q101</cusip>
    <isin>US74766Q1013</isin>
    <meetingDate>06/03/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as the independent accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>18837.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>18837.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Election of Directors: Dawn Svoronos</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Election of Directors: Gillian Cannon</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Election of Directors: Steven Gannon</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Election of Directors: Elizabeth Garofalo</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Election of Directors: Justin Gover</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Election of Directors: Pat Machado</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Election of Directors: Ian Mortimer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Election of Directors: Gary Patou</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the Corporation's named executive officers</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Amendment to the Amended and Restated 2014 Plan Approve certain amendments to the Amended and Restated 2014 Equity Incentive Plan, including to increase the maximum number of Common Shares available for issuance thereunder by 5,200,000</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Appointment of Auditor Appoint KPMG LLP as the Corporation's auditor to hold office until the next annual meeting of the Corporation or until their successors are duly elected</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xenon Pharmaceuticals Inc.</issuerName>
    <cusip>98420N105</cusip>
    <isin>CA98420N1050</isin>
    <meetingDate>06/04/2024</meetingDate>
    <voteDescription>Remuneration of Auditor Authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditor of the Corporation</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>32036.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>32036.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Apellis Pharmaceuticals, Inc.</issuerName>
    <cusip>03753U106</cusip>
    <isin>US03753U1060</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Paul Fonteyne</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71177.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>71177.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Apellis Pharmaceuticals, Inc.</issuerName>
    <cusip>03753U106</cusip>
    <isin>US03753U1060</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Election of two Class I directors to hold office until the 2027 annual meeting of stockholders: Stephanie Monaghan O'Brien</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71177.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>71177.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Apellis Pharmaceuticals, Inc.</issuerName>
    <cusip>03753U106</cusip>
    <isin>US03753U1060</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71177.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>71177.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Apellis Pharmaceuticals, Inc.</issuerName>
    <cusip>03753U106</cusip>
    <isin>US03753U1060</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Approval of an advisory vote on executive compensation; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>71177.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>71177.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 1 - Ordinary Resolution THAT Dr. Olivier Brandicourt be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 2 - Ordinary Resolution THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 3 - Ordinary Resolution THAT Michael Goller be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 4 - Ordinary Resolution THAT Dr. Corazon (Corsee) D. Sanders be and is hereby re-elected to serve as a Class II director of the Company until the 2027 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 5 - Ordinary Resolution THAT the appointment of Ernst &amp; Young LLP, Ernst &amp; Young and Ernst &amp; Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2024 be and is hereby approved, ratified and confirmed.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 6 - Ordinary Resolution THAT the Board of Directors is hereby authorized to fix the auditors' compensation for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 7 - Ordinary Resolution THAT the granting of a share issue mandate to the Board of Directors to issue, allot or deal with unissued ordinary shares and/or American Depositary Shares ("ADSs") (including any sale or transfer of treasury shares (which shall have the meaning ascribed to it under the HK Listing Rules coming into effect on June 11, 2024) out of treasury) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as of the date of passing of this ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 8 - Ordinary Resolution THAT the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding RMB shares) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares and treasury shares) of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 9 - Ordinary Resolution THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to each of Baker Bros. Advisors LP and Hillhouse Capital Management, Ltd. and parties affiliated with each of them (the "Existing Shareholders"), up to a maximum amount of shares in order to maintain the same shareholding percentage of each of the Existing Shareholders (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 7 for a period of five years, which period will be subject to an extension on a rolling basis each year.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 10 - Ordinary Resolution THAT the Company and its underwriters be and are hereby authorized, in their sole discretion, to allocate to Amgen Inc. ("Amgen"), up to a maximum amount of shares in order to maintain the same shareholding percentage of Amgen (based on the then-outstanding share capital of the Company) before and after the allocation of the corresponding securities issued pursuant to an offering conducted pursuant to the general mandate set forth in Resolution 7 for a period of five years, which period will be subject to an extension on a rolling basis each year.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 11 - Ordinary Resolution THAT the grant of restricted share units ("RSUs") with a grant date fair value of US$6,000,000 to Mr. John V. Oyler under the Second Amended and Restated 2016 Share Option and Incentive Plan (as amended, the "2016 Plan"), according to the terms and conditions described in the Proxy Statement, be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 12 - Ordinary Resolution THAT the grant of performance share units ("PSUs") with a grant date fair value of US$6,000,000 to Mr. John V. Oyler under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 13 - Ordinary Resolution THAT the grant of RSUs with a grant date fair value of US$1,333,333 to Dr. Xiaodong Wang under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 14 - Ordinary Resolution THAT the grant of RSUs with a grant date fair value of US$200,000 to each of the independent non-executive directors, Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Alessandro Riva, Dr. Corazon (Corsee) D. Sanders, and Mr. Qingqing Yi, under the 2016 Plan, according to the terms and conditions described in the Proxy Statement, be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 15 - Ordinary Resolution THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 16 - Ordinary Resolution THAT, on a non-binding, advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 17(a) - Ordinary Resolution THAT the Third Amended and Restated 2016 Share Option and Incentive Plan of the Company, as described in the Proxy Statement, be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 17(b) - Ordinary Resolution THAT the consultant sublimit set out in the Third Amended and Restated 2016 Share Option and Incentive Plan of the Company, as described in the Proxy Statement, be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 18 - Ordinary Resolution THAT the Fourth Amended and Restated 2018 Employee Share Purchase Plan of the Company, as described in the Proxy Statement, be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BeiGene, Ltd.</issuerName>
    <cusip>07725L102</cusip>
    <isin>US07725L1026</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Resolution 19 - Ordinary Resolution THAT the adjournment of the Annual Meeting by the chairman, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve any of the proposals described above, be and is hereby approved.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>16838.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>16838.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mirum Pharmaceuticals, Inc.</issuerName>
    <cusip>604749101</cusip>
    <isin>US6047491013</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Laurent Fischer, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33568.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>33568.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mirum Pharmaceuticals, Inc.</issuerName>
    <cusip>604749101</cusip>
    <isin>US6047491013</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Patrick J. Heron</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33568.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>33568.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mirum Pharmaceuticals, Inc.</issuerName>
    <cusip>604749101</cusip>
    <isin>US6047491013</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Election of three Class II nominees for director to hold office until the Company's 2027 annual meeting of stockholders: Saira Ramasastry, M.S., M.Phil.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33568.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>33568.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mirum Pharmaceuticals, Inc.</issuerName>
    <cusip>604749101</cusip>
    <isin>US6047491013</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of Ernst &amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33568.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>33568.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mirum Pharmaceuticals, Inc.</issuerName>
    <cusip>604749101</cusip>
    <isin>US6047491013</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33568.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>33568.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Mirum Pharmaceuticals, Inc.</issuerName>
    <cusip>604749101</cusip>
    <isin>US6047491013</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>33568.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>33568.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Praxis Precision Medicines, Inc.</issuerName>
    <cusip>74006W207</cusip>
    <isin>US74006W2070</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified: Dean Mitchell</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1572.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>1572.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Praxis Precision Medicines, Inc.</issuerName>
    <cusip>74006W207</cusip>
    <isin>US74006W2070</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified: Jill DeSimone</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1572.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>1572.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Praxis Precision Medicines, Inc.</issuerName>
    <cusip>74006W207</cusip>
    <isin>US74006W2070</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>To ratify the selection of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1572.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>1572.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Praxis Precision Medicines, Inc.</issuerName>
    <cusip>74006W207</cusip>
    <isin>US74006W2070</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>To approve the amendment and restatement of the Company's 2020 Stock Option and Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1572.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1572.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Praxis Precision Medicines, Inc.</issuerName>
    <cusip>74006W207</cusip>
    <isin>US74006W2070</isin>
    <meetingDate>06/05/2024</meetingDate>
    <voteDescription>To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2024 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>1572.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>1572.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Joshua B. Cohen</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35392.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>35392.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Daphne Quimi</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35392.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>35392.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35392.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>35392.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executives officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35392.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>35392.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
    <cusip>03237H101</cusip>
    <isin>US03237H1014</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To vote, on a non-binding, advisory basis, on the preferred frequency of future advisory votes on the compensation of our named executives officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>35392.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>35392.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HilleVax, Inc.</issuerName>
    <cusip>43157M102</cusip>
    <isin>US43157M1027</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To elect three directors to serve as Class II directors for a three-year term to expire at the 2027 annual meeting of stockholders: Gary Dubin, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HilleVax, Inc.</issuerName>
    <cusip>43157M102</cusip>
    <isin>US43157M1027</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To elect three directors to serve as Class II directors for a three-year term to expire at the 2027 annual meeting of stockholders: Patrick Heron</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HilleVax, Inc.</issuerName>
    <cusip>43157M102</cusip>
    <isin>US43157M1027</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To elect three directors to serve as Class II directors for a three-year term to expire at the 2027 annual meeting of stockholders: Jaime Sepulveda, M.D., D.Sc., M.P.H.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HilleVax, Inc.</issuerName>
    <cusip>43157M102</cusip>
    <isin>US43157M1027</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>HilleVax, Inc.</issuerName>
    <cusip>43157M102</cusip>
    <isin>US43157M1027</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To approve an amendment to our Amended and Restated Certificate of Incorporation to reflect Delaware law provisions to permit exculpation of certain officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>27000.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>27000.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: Brett P. Monia</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>92878.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>92878.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: Michael Yang</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>92878.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>92878.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To make an advisory vote on executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>92878.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>92878.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 3,300,000 shares to an aggregate of 38,500,000 shares and to prohibit certain share recycling on full value awards.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>92878.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>92878.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ionis Pharmaceuticals, Inc.</issuerName>
    <cusip>462222100</cusip>
    <isin>US4622221004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>To ratify the Audit Committee's selection of Ernst &amp; Young LLP as independent auditors for the 2024 fiscal year.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>92878.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>92878.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: Pablo Legorreta</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: Henry Fernandez</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: Bonnie Bassler , Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: Errol De Souza, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: Catherine Engelbert</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: David Hodgson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: Ted Love , M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Directors: Gregory Norden</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>A non-binding advisory vote to approve executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports for the fiscal year ended December 31, 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Approve our U.K. directors' remuneration policy.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containing the directors' remuneration policy) for the fiscal year ended December 31, 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Re-appoint Ernst &amp; Young as our U.K. statutory auditor, to hold office until the conclusion of the next general meeting at which the U.K. annual report and accounts are presented to shareholders.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Authorize the Board to determine the remuneration of Ernst &amp; Young in its capacity as our U.K. statutory auditor.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Authorize the Board to allot shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Royalty Pharma Plc</issuerName>
    <cusip>G7709Q104</cusip>
    <isin>GB00BMVP7Y09</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Authorize the Board to allot shares without rights of pre-emption (special resolution).</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>155069.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>155069.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Douglas S. Ingram</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>59641.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>59641.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Hans Wigzell, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>59641.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>59641.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Kathryn J. Boor, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>59641.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>59641.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Michael Chambers</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>59641.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>59641.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>advisory vote to approve, on a non-binding basis, name executive officer compensation</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>59641.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>59641.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Sarepta Therapeutics, Inc.</issuerName>
    <cusip>803607100</cusip>
    <isin>US8036071004</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>59641.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>59641.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Annie Drapeau</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>61919.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>61919.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Teri Loxam</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>61919.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>61919.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Election of Class I Directors Nominees would serve until the 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Carlos Paya, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>61919.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>61919.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>61919.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>61919.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Vaxcyte, Inc.</issuerName>
    <cusip>92243G108</cusip>
    <isin>US92243G1085</isin>
    <meetingDate>06/06/2024</meetingDate>
    <voteDescription>Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>61919.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>61919.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Adaptive Biotechnologies Corporation</issuerName>
    <cusip>00650F109</cusip>
    <isin>US00650F1093</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2027 annual meeting of shareholders: Peter Neupert</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>381660.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>381660.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Adaptive Biotechnologies Corporation</issuerName>
    <cusip>00650F109</cusip>
    <isin>US00650F1093</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2027 annual meeting of shareholders: Michelle Griffin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>381660.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>381660.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Adaptive Biotechnologies Corporation</issuerName>
    <cusip>00650F109</cusip>
    <isin>US00650F1093</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>381660.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>381660.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Adaptive Biotechnologies Corporation</issuerName>
    <cusip>00650F109</cusip>
    <isin>US00650F1093</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the year ending December 31, 2024; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>381660.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>381660.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Seth L. Harrison, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>83383.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>83383.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Graham Walmsley, M.D., Ph.D</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>83383.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>83383.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>Election of Class II Directors to serve until the 2027 annual meeting of stockholders and until his or her successor has been duly elected and qualified: Yuan Xu, Ph.D</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>83383.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>83383.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>83383.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>83383.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>83383.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>83383.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Akero Therapeutics, Inc.</issuerName>
    <cusip>00973Y108</cusip>
    <isin>US00973Y1082</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To approve an Amendment to our Fourth Amended and Restated Certificate of Incorporation, to limit the liability of certain officers of Akero Therapeutics, Inc., as permitted by recent amendments to Delaware law.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>83383.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>83383.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Crinetics Pharmaceuticals, Inc.</issuerName>
    <cusip>22663K107</cusip>
    <isin>US22663K1079</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Camille Bedrosian, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101196.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>101196.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Crinetics Pharmaceuticals, Inc.</issuerName>
    <cusip>22663K107</cusip>
    <isin>US22663K1079</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Wendell Wierenga, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101196.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>101196.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Crinetics Pharmaceuticals, Inc.</issuerName>
    <cusip>22663K107</cusip>
    <isin>US22663K1079</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101196.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>101196.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Crinetics Pharmaceuticals, Inc.</issuerName>
    <cusip>22663K107</cusip>
    <isin>US22663K1079</isin>
    <meetingDate>06/07/2024</meetingDate>
    <voteDescription>To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>101196.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>101196.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SAGE Therapeutics, Inc.</issuerName>
    <cusip>78667J108</cusip>
    <isin>US78667J1088</isin>
    <meetingDate>06/10/2024</meetingDate>
    <voteDescription>To elect two directors, Elizabeth Barrett and Geno Germano, each to serve as a Class I director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier death, resignation, or removal: Elizabeth Barrett</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>22773.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SAGE Therapeutics, Inc.</issuerName>
    <cusip>78667J108</cusip>
    <isin>US78667J1088</isin>
    <meetingDate>06/10/2024</meetingDate>
    <voteDescription>To elect two directors, Elizabeth Barrett and Geno Germano, each to serve as a Class I director until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier death, resignation, or removal: Geno Germano</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>22773.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SAGE Therapeutics, Inc.</issuerName>
    <cusip>78667J108</cusip>
    <isin>US78667J1088</isin>
    <meetingDate>06/10/2024</meetingDate>
    <voteDescription>To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>22773.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SAGE Therapeutics, Inc.</issuerName>
    <cusip>78667J108</cusip>
    <isin>US78667J1088</isin>
    <meetingDate>06/10/2024</meetingDate>
    <voteDescription>To hold a non-binding advisory vote to approve the compensation paid to our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>22773.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>SAGE Therapeutics, Inc.</issuerName>
    <cusip>78667J108</cusip>
    <isin>US78667J1088</isin>
    <meetingDate>06/10/2024</meetingDate>
    <voteDescription>To approve the Sage Therapeutics, Inc. 2024 Equity Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>22773.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>22773.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Codexis, Inc.</issuerName>
    <cusip>192005106</cusip>
    <isin>US1920051067</isin>
    <meetingDate>06/11/2024</meetingDate>
    <voteDescription>Election of the two Class II directors named in the Proxy Statement to hold office for a three-year term expiring at the 2027 Annual Meeting: Esther Martinborough, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>160581.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>160581.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Codexis, Inc.</issuerName>
    <cusip>192005106</cusip>
    <isin>US1920051067</isin>
    <meetingDate>06/11/2024</meetingDate>
    <voteDescription>Election of the two Class II directors named in the Proxy Statement to hold office for a three-year term expiring at the 2027 Annual Meeting: H. Stewart Parker</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>160581.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>160581.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Codexis, Inc.</issuerName>
    <cusip>192005106</cusip>
    <isin>US1920051067</isin>
    <meetingDate>06/11/2024</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of our board of directors of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>160581.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>160581.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Codexis, Inc.</issuerName>
    <cusip>192005106</cusip>
    <isin>US1920051067</isin>
    <meetingDate>06/11/2024</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>160581.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>160581.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>06/11/2024</meetingDate>
    <voteDescription>The election of one Class I director and three Class III directors named in the proxy statement: Santhosh Palani, Ph.D., CFA</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>226657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>226657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>06/11/2024</meetingDate>
    <voteDescription>The election of one Class I director and three Class III directors named in the proxy statement: John Flavin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>226657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>226657.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>06/11/2024</meetingDate>
    <voteDescription>The election of one Class I director and three Class III directors named in the proxy statement: Lara Sullivan, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>226657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>226657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>06/11/2024</meetingDate>
    <voteDescription>The election of one Class I director and three Class III directors named in the proxy statement: Jakob Dupont, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>226657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>226657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Pyxis Oncology, Inc.</issuerName>
    <cusip>747324101</cusip>
    <isin>US7473241013</isin>
    <meetingDate>06/11/2024</meetingDate>
    <voteDescription>The ratification of the appointment of Emst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>226657.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>226657.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ALX Oncology Holdings, Inc.</issuerName>
    <cusip>00166B105</cusip>
    <isin>US00166B1052</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Election of Directors: Corey Goodman, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>66211.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>66211.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ALX Oncology Holdings, Inc.</issuerName>
    <cusip>00166B105</cusip>
    <isin>US00166B1052</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Election of Directors: Jason Lettmann</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>66211.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>66211.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ALX Oncology Holdings, Inc.</issuerName>
    <cusip>00166B105</cusip>
    <isin>US00166B1052</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Election of Directors: Sophia Randolph, M.D., Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>66211.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>66211.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ALX Oncology Holdings, Inc.</issuerName>
    <cusip>00166B105</cusip>
    <isin>US00166B1052</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Advisory vote to approve named executive officer compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>66211.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>66211.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>ALX Oncology Holdings, Inc.</issuerName>
    <cusip>00166B105</cusip>
    <isin>US00166B1052</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for our fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>66211.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>66211.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Election of Class III Directors: Helmy Eltoukhy</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67056.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67056.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Election of Class III Directors: Steve Krognes</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67056.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>67056.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Election of Class III Directors: AmirAli Talasaz</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67056.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67056.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Deloitte &amp; Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67056.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67056.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Guardant Health, Inc.</issuerName>
    <cusip>40131M109</cusip>
    <isin>US40131M1099</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67056.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67056.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Intellia Therapeutics, Inc.</issuerName>
    <cusip>45826J105</cusip>
    <isin>US45826J1051</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Fred Cohen, M.D., D.Phil.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50605.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50605.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Intellia Therapeutics, Inc.</issuerName>
    <cusip>45826J105</cusip>
    <isin>US45826J1051</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Frank Verwiel, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50605.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>50605.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Intellia Therapeutics, Inc.</issuerName>
    <cusip>45826J105</cusip>
    <isin>US45826J1051</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Deloitte &amp; Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50605.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50605.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Intellia Therapeutics, Inc.</issuerName>
    <cusip>45826J105</cusip>
    <isin>US45826J1051</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Approve, on a non-binding advisory basis, the compensation of the named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50605.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50605.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Intellia Therapeutics, Inc.</issuerName>
    <cusip>45826J105</cusip>
    <isin>US45826J1051</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>Approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>50605.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>50605.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Natera, Inc.</issuerName>
    <cusip>632307104</cusip>
    <isin>US6323071042</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To elect the three directors named below and in the proxy statement to serve as Class III directors until the annual meeting of stockholders to be held in 2027 and until their successors are duly elected and qualified: Roelof Botha</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47269.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>47269.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Natera, Inc.</issuerName>
    <cusip>632307104</cusip>
    <isin>US6323071042</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To elect the three directors named below and in the proxy statement to serve as Class III directors until the annual meeting of stockholders to be held in 2027 and until their successors are duly elected and qualified: Steven Chapman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47269.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47269.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Natera, Inc.</issuerName>
    <cusip>632307104</cusip>
    <isin>US6323071042</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To elect the three directors named below and in the proxy statement to serve as Class III directors until the annual meeting of stockholders to be held in 2027 and until their successors are duly elected and qualified: Matthew Rabinowitz</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47269.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47269.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Natera, Inc.</issuerName>
    <cusip>632307104</cusip>
    <isin>US6323071042</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47269.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47269.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Natera, Inc.</issuerName>
    <cusip>632307104</cusip>
    <isin>US6323071042</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47269.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>47269.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Natera, Inc.</issuerName>
    <cusip>632307104</cusip>
    <isin>US6323071042</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To approve Natera, Inc.'s amended and restated 2015 Equity Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>47269.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>47269.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>TScan Therapeutics, Inc.</issuerName>
    <cusip>89854M101</cusip>
    <isin>US89854M1018</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To elect two Class III directors to the Company's Board of Directors: Gabriela Gruia, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>61943.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>61943.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>TScan Therapeutics, Inc.</issuerName>
    <cusip>89854M101</cusip>
    <isin>US89854M1018</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To elect two Class III directors to the Company's Board of Directors: Barbara Klencke, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>61943.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>61943.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>TScan Therapeutics, Inc.</issuerName>
    <cusip>89854M101</cusip>
    <isin>US89854M1018</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>61943.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>61943.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>TScan Therapeutics, Inc.</issuerName>
    <cusip>89854M101</cusip>
    <isin>US89854M1018</isin>
    <meetingDate>06/12/2024</meetingDate>
    <voteDescription>To approve the Company's Amended and Restated 2021 Equity Incentive Plan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>61943.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>61943.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Carsten Boess</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>129414.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>129414.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Sarah Boyce</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>129414.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>129414.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect three directors to serve as Class I directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Dr. Troy Wilson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>129414.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>129414.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To ratify the appointment of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>129414.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>129414.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Avidity Biosciences, Inc.</issuerName>
    <cusip>05370A108</cusip>
    <isin>US05370A1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in the related proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>129414.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>129414.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Caribou Biosciences, Inc.</issuerName>
    <cusip>142038108</cusip>
    <isin>US1420381089</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Election of three Class III directors to serve until the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier death, resignation or removal. The three nominees for election are: Rachel Haurwitz, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>181487.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>181487.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Caribou Biosciences, Inc.</issuerName>
    <cusip>142038108</cusip>
    <isin>US1420381089</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Election of three Class III directors to serve until the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier death, resignation or removal. The three nominees for election are: Dara Richardson-Heron, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>181487.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>181487.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Caribou Biosciences, Inc.</issuerName>
    <cusip>142038108</cusip>
    <isin>US1420381089</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Election of three Class III directors to serve until the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier death, resignation or removal. The three nominees for election are: Natalie Sacks, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>181487.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>181487.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Caribou Biosciences, Inc.</issuerName>
    <cusip>142038108</cusip>
    <isin>US1420381089</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>181487.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>181487.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>G1 Therapeutics, Inc.</issuerName>
    <cusip>3621LQ109</cusip>
    <isin>US3621LQ1099</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>The election of two Class I directors: John E. Bailey, Jr.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>223377.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>223377.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>G1 Therapeutics, Inc.</issuerName>
    <cusip>3621LQ109</cusip>
    <isin>US3621LQ1099</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>The election of two Class I directors: Cynthia L. Flowers</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>223377.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>223377.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>G1 Therapeutics, Inc.</issuerName>
    <cusip>3621LQ109</cusip>
    <isin>US3621LQ1099</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>An advisory (non-binding) vote to approve executive compensation</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>223377.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>223377.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>G1 Therapeutics, Inc.</issuerName>
    <cusip>3621LQ109</cusip>
    <isin>US3621LQ1099</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2024</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>223377.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>223377.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>G1 Therapeutics, Inc.</issuerName>
    <cusip>3621LQ109</cusip>
    <isin>US3621LQ1099</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Approval of the amendment and restatement of G1 Therapeutics, Inc.'s Certificate of Incorporation to reflect new Delaware law on provisions regarding officer exculpation</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>223377.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>223377.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nkarta, Inc.</issuerName>
    <cusip>65487U108</cusip>
    <isin>US65487U1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Election of three directors to serve until the company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified: Paul Hastings</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>28988.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>28988.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nkarta, Inc.</issuerName>
    <cusip>65487U108</cusip>
    <isin>US65487U1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Election of three directors to serve until the company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified: Angela Thedinga, M.B.A., M.P.H.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>28988.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>28988.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nkarta, Inc.</issuerName>
    <cusip>65487U108</cusip>
    <isin>US65487U1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Election of three directors to serve until the company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified: George Vratsanos, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>28988.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>28988.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nkarta, Inc.</issuerName>
    <cusip>65487U108</cusip>
    <isin>US65487U1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as the company's independent registered public accounting firm for the year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>28988.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>28988.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Nkarta, Inc.</issuerName>
    <cusip>65487U108</cusip>
    <isin>US65487U1088</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Approval of an amendment to the company's Certificate of Incorporation to increase the number of total authorized shares of the company's common stock, $0.0001 par value per share, from 100,000,000 to 200,000,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>28988.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>28988.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Election of Class II directors to serve on the Board of Directors, each for a three-year term expiring at the 2027 Annual Meeting of Stockholders: Richard H. Douglas, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Election of Class II directors to serve on the Board of Directors, each for a three-year term expiring at the 2027 Annual Meeting of Stockholders: Margaret G. McGlynn, R.Ph.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Election of Class II directors to serve on the Board of Directors, each for a three-year term expiring at the 2027 Annual Meeting of Stockholders: David Mott</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>The approval, on an advisory basis, of the compensation paid to our Named Executive Officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Amendment and Restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan to increase the number of shares of common stock available for issuance thereunder by 6,500,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Amendment and restatement of the Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan to increase the number of shares of common stock available for issuance thereunder by 1,000,000 shares, such that the number of shares available for issuance thereunder is the lesser of (a) 2,155,000 shares of common stock increased on January 1 of each year by 5% of the share pool on such January 1 (rounded down to the nearest whole share) and (b) 3,510,264 shares of common stock.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Novavax, Inc.</issuerName>
    <cusip>670002401</cusip>
    <isin>US6700024010</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>26612.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>26612.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tarsus Pharmaceuticals, Inc.</issuerName>
    <cusip>87650L103</cusip>
    <isin>US87650L1035</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To re-elect the following two nominees as Class I directors, to serve until the 2027 annual meeting of stockholders or until their respective successor have been elected or appointed: Bhaskar Chaudhuri</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72032.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>72032.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tarsus Pharmaceuticals, Inc.</issuerName>
    <cusip>87650L103</cusip>
    <isin>US87650L1035</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To re-elect the following two nominees as Class I directors, to serve until the 2027 annual meeting of stockholders or until their respective successor have been elected or appointed: William J. Link</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72032.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>72032.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Tarsus Pharmaceuticals, Inc.</issuerName>
    <cusip>87650L103</cusip>
    <isin>US87650L1035</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>72032.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>72032.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Bassil I. Dahiyat</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Ellen G. Feigal</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Kevin C. Gorman</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Kurt A. Gustafson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Barbara Klencke</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. A. Bruce Montgomery</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Richard J. Ranieri</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Ms. Dagmar Rosa-Bjorkeson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To ratify the selection by the Audit Committee of the Board of Directors of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Xencor, Inc.</issuerName>
    <cusip>98401F105</cusip>
    <isin>US98401F1057</isin>
    <meetingDate>06/13/2024</meetingDate>
    <voteDescription>To approve, by non-binding advisory vote, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>97385.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>97385.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Election of Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Terrie Curran</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>62005.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>62005.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Election of Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Halley E. Gilbert</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>62005.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>62005.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Election of Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected: Keith R. Leonard, Jr.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>62005.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>62005.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst &amp; Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>62005.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>62005.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Arcutis Biotherapeutics, Inc.</issuerName>
    <cusip>03969K108</cusip>
    <isin>US03969K1088</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>62005.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>62005.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To elect two Class I directors to hold office until the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Onaiza Cadoret-Manier</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>378872.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>378872.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To elect two Class I directors to hold office until the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: William A. Bertrand, Jr., Esq.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>378872.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>378872.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To approve the Amended and Restated 2014 Equity Incentive Award Plan;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>378872.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>378872.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To approve the Amended and Restated 2014 Employee Stock Purchase Plan;</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>378872.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>378872.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the proxy statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay");</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>378872.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>378872.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ardelyx, Inc.</issuerName>
    <cusip>039697107</cusip>
    <isin>US0396971071</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To ratify the selection, by the Audit and Compliance Committee of our Board of Directors, of Ernst &amp; Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>378872.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>378872.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Intra-Cellular Therapies, Inc.</issuerName>
    <cusip>46116X101</cusip>
    <isin>US46116X1019</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To elect one director to serve a three-year term expiring in 2027: Joel S. Marcus</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67216.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67216.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Intra-Cellular Therapies, Inc.</issuerName>
    <cusip>46116X101</cusip>
    <isin>US46116X1019</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To approve the amendment and restatement of the Company's Amended and Restated 2018 Equity Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67216.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67216.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Intra-Cellular Therapies, Inc.</issuerName>
    <cusip>46116X101</cusip>
    <isin>US46116X1019</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To ratify of the appointment of Ernst &amp; Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67216.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67216.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Intra-Cellular Therapies, Inc.</issuerName>
    <cusip>46116X101</cusip>
    <isin>US46116X1019</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>67216.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>67216.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Election of Directors: N. Anthony Coles, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44519.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44519.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Election of Directors: Kathryn Guarini, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44519.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44519.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Election of Directors: Arthur F. Ryan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44519.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>44519.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Election of Directors: David P. Schenkein, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44519.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44519.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Election of Directors: George L. Sing</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44519.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44519.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44519.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44519.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Proposal to approve, on an advisory basis, executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>44519.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44519.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Regeneron Pharmaceuticals, Inc.</issuerName>
    <cusip>75886F107</cusip>
    <isin>US75886F1075</isin>
    <meetingDate>06/14/2024</meetingDate>
    <voteDescription>Non-binding shareholder proposal requesting simple majority voting requirements, if properly presented.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>SECURITY HOLDER</voteSource>
    <sharesVoted>44519.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>44519.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/17/2024</meetingDate>
    <voteDescription>Election of three Class II directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders: James Collins</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256888.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>256888.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/17/2024</meetingDate>
    <voteDescription>Election of three Class II directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders: James Geraghty</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256888.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>256888.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/17/2024</meetingDate>
    <voteDescription>Election of three Class II directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders: Alex Sapir</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256888.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>256888.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Fulcrum Therapeutics, Inc.</issuerName>
    <cusip>359616109</cusip>
    <isin>US3596161097</isin>
    <meetingDate>06/17/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>256888.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>256888.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Nominees: Deborah Dunsire, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>42475.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>42475.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Nominees: Michael Narachi</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>42475.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>42475.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Nominees: Corsee D. Sanders, Ph.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>42475.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>42475.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Approval of the Amended and Restated 2023 Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>42475.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>42475.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Ratification of the selection of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>42475.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>42475.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Ultragenyx Pharmaceutical Inc.</issuerName>
    <cusip>90400D108</cusip>
    <isin>US90400D1081</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Advisory (non-binding) vote to approve the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>42475.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>42475.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Adoption of the 2023 Dutch statutory annual accounts for the fiscal year ended December 3, 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Discharge of liability of the members of the Board for their management during the fiscal year ended December 31, 2023.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Reappointment of Rachelle Jacques as non-executive director.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Reappointment of David Meek as non-executive director.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Authorization of the Board to issue Ordinary Shares and grant rights to subscribe for Ordinary Shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Authorization of the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Authorization of the Board to repurchase Ordinary Shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Appointment of KPMG as external auditors of the Company for the financial year 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Approval, on an advisory basis, of the compensation of the named executive officers of the Company.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>uniQure N.V.</issuerName>
    <cusip>N90064101</cusip>
    <isin>NL0010696654</isin>
    <meetingDate>06/18/2024</meetingDate>
    <voteDescription>Resolution to adopt the Amendment to the 2014 Share Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>156394.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>156394.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Caroline D. Dorsa</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Maria C. Freire</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: William A. Hawkins</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Susan K. Langer</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Jesus B. Mantas</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Monish Patolawala</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Eric K. Rowinsky</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Stephen A. Sherwin</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Election of Directors. To elect the 9 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2025 annual meeting of stockholders and their successors are duly elected and qualified: Christopher A. Viehbacher</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>Say on Pay - To hold an advisory vote on executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>To approve an amendment to Biogen's Amended and Restated Certificate of Incorporation, as amended, to add an officer exculpation provision.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>To approve the Biogen Inc. 2024 Omnibus Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Biogen Inc.</issuerName>
    <cusip>09062X103</cusip>
    <isin>US09062X1037</isin>
    <meetingDate>06/20/2024</meetingDate>
    <voteDescription>To approve the Biogen Inc. 2024 Employee Stock Purchase Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>70486.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>70486.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BridgeBio Pharma, Inc.</issuerName>
    <cusip>10806X102</cusip>
    <isin>US10806X1028</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Eric Aguiar, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38855.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38855.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BridgeBio Pharma, Inc.</issuerName>
    <cusip>10806X102</cusip>
    <isin>US10806X1028</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Jennifer E. Cook</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38855.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38855.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BridgeBio Pharma, Inc.</issuerName>
    <cusip>10806X102</cusip>
    <isin>US10806X1028</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Andrea J. Ellis</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38855.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38855.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BridgeBio Pharma, Inc.</issuerName>
    <cusip>10806X102</cusip>
    <isin>US10806X1028</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Fred Hassan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38855.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38855.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BridgeBio Pharma, Inc.</issuerName>
    <cusip>10806X102</cusip>
    <isin>US10806X1028</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Ali J. Satvat</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38855.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>38855.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BridgeBio Pharma, Inc.</issuerName>
    <cusip>10806X102</cusip>
    <isin>US10806X1028</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38855.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>38855.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BridgeBio Pharma, Inc.</issuerName>
    <cusip>10806X102</cusip>
    <isin>US10806X1028</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To ratify the appointment of Deloitte &amp; Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38855.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>38855.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>BridgeBio Pharma, Inc.</issuerName>
    <cusip>10806X102</cusip>
    <isin>US10806X1028</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 6,500,000 shares.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>38855.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>38855.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Zentalis Pharmaceuticals, Inc.</issuerName>
    <cusip>98943L107</cusip>
    <isin>US98943L1070</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Kimberly Blackwell, M.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2153.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2153.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Zentalis Pharmaceuticals, Inc.</issuerName>
    <cusip>98943L107</cusip>
    <isin>US98943L1070</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Enoch Kariuki, Pharm.D.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2153.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>2153.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Zentalis Pharmaceuticals, Inc.</issuerName>
    <cusip>98943L107</cusip>
    <isin>US98943L1070</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2153.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>2153.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Zentalis Pharmaceuticals, Inc.</issuerName>
    <cusip>98943L107</cusip>
    <isin>US98943L1070</isin>
    <meetingDate>06/21/2024</meetingDate>
    <voteDescription>To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>2153.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>2153.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Flamingo Therapeutics, Inc.</issuerName>
    <meetingDate>06/24/2024</meetingDate>
    <voteDescription>Acknowledgment of the report of the statutory auditor</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107120.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107120.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Flamingo Therapeutics, Inc.</issuerName>
    <meetingDate>06/24/2024</meetingDate>
    <voteDescription>Approval of the annual accounts for the fiscal year ended on 31 December 2023</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107120.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107120.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Flamingo Therapeutics, Inc.</issuerName>
    <meetingDate>06/24/2024</meetingDate>
    <voteDescription>Allocation of the results</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107120.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107120.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Flamingo Therapeutics, Inc.</issuerName>
    <meetingDate>06/24/2024</meetingDate>
    <voteDescription>Release of liability to the directors and the statutory auditor for the exercise of their mandate during the past fiscal year (and for presentation of the annual accounts at a date other than the statutory date)</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107120.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107120.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Flamingo Therapeutics, Inc.</issuerName>
    <meetingDate>06/24/2024</meetingDate>
    <voteDescription>Acknowledgement of the resignations of directors and confirmation of the appointment of Dr. Ezra Cohen as independent director, following cooptation by the Board of Directors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107120.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107120.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Flamingo Therapeutics, Inc.</issuerName>
    <meetingDate>06/24/2024</meetingDate>
    <voteDescription>Acknowledgement of the change to permanent representative of KPMG Bedrijfsrevisoren (appointment of Mr. Paul Dreezen)</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107120.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107120.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Flamingo Therapeutics, Inc.</issuerName>
    <meetingDate>06/24/2024</meetingDate>
    <voteDescription>Proxy for publications</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>107120.000000</sharesVoted>
    <sharesOnLoan>0.000000</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>107120.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Adopt Financial Statements and Statutory Reports</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Approve Discharge of Management Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Approve Discharge of Supervisory Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Reelect Andreas Harstrick to Management Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Reelect Wolfgang Fischer to Management Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Reelect Denise Michele Mueller to Management Board</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Approve Increase in Authorized Share Capital and Amend Articles of Association</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Grant Board Authority to Issue Shares</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Authorize Board to Exclude Preemptive Rights from Share Issuances</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Approve Cancellation of Shares</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Affimed NV</issuerName>
    <cusip>N01045207</cusip>
    <isin>NL0015001ZQ0</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Ratify KPMG Accountants N.V. as Auditors</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>20862.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>20862.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Christopher Causey</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Raymond Dwek</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Richard Giltner</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Ray Kurzweil</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Jan Malcolm</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Linda Maxwell</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Nilda Mesa</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Judy Olian</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Christopher Patusky</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Martine Rothblatt</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Louis Sullivan</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Election of Directors: Tommy Thompson</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Advisory resolution to approve executive compensation.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>COMPENSATION</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>United Therapeutics Corporation</issuerName>
    <cusip>91307C102</cusip>
    <isin>US91307C1027</isin>
    <meetingDate>06/26/2024</meetingDate>
    <voteDescription>Ratification of the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>9880.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>AGAINST</howVoted>
        <sharesVoted>9880.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Scholar Rock Holding Corporation</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>06/27/2024</meetingDate>
    <voteDescription>To elect three Class III directors to our Board of Directors, each to serve until the 2027 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Richard Brudnick</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>151495.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>151495.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Scholar Rock Holding Corporation</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>06/27/2024</meetingDate>
    <voteDescription>To elect three Class III directors to our Board of Directors, each to serve until the 2027 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Jeffrey S. Flier</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>151495.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>151495.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Scholar Rock Holding Corporation</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>06/27/2024</meetingDate>
    <voteDescription>To elect three Class III directors to our Board of Directors, each to serve until the 2027 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Akshay Vaishnaw</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>DIRECTOR ELECTIONS</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>151495.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>WITHHOLD</howVoted>
        <sharesVoted>151495.000000</sharesVoted>
        <managementRecommendation>AGAINST</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Scholar Rock Holding Corporation</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>06/27/2024</meetingDate>
    <voteDescription>To ratify the appointment of Ernst &amp; Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>AUDIT-RELATED</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>151495.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>151495.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Scholar Rock Holding Corporation</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>06/27/2024</meetingDate>
    <voteDescription>To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CAPITAL STRUCTURE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>151495.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>151495.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Scholar Rock Holding Corporation</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>06/27/2024</meetingDate>
    <voteDescription>To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>CORPORATE GOVERNANCE</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>151495.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>151495.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Scholar Rock Holding Corporation</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>06/27/2024</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>151495.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>FOR</howVoted>
        <sharesVoted>151495.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
  <proxyTable>
    <issuerName>Scholar Rock Holding Corporation</issuerName>
    <cusip>80706P103</cusip>
    <isin>US80706P1030</isin>
    <meetingDate>06/27/2024</meetingDate>
    <voteDescription>To approve, on a non-binding, advisory basis, the preferred frequency of future advisory votes on compensation of our named executive officers.</voteDescription>
    <voteCategories>
      <voteCategory>
        <categoryType>SECTION 14A SAY-ON-PAY VOTES</categoryType>
      </voteCategory>
    </voteCategories>
    <voteSource>ISSUER</voteSource>
    <sharesVoted>151495.000000</sharesVoted>
    <sharesOnLoan>0</sharesOnLoan>
    <vote>
      <voteRecord>
        <howVoted>ONE YEAR</howVoted>
        <sharesVoted>151495.000000</sharesVoted>
        <managementRecommendation>FOR</managementRecommendation>
      </voteRecord>
    </vote>
  </proxyTable>
</proxyVoteTable>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
